A potential factor that your physician might overlook when prescribing medications is your genetic makeup.
Research released on Wednesday in Science Translational Medicine indicated that almost 25% of study participants had been given a medication that might have necessitated a different drug or dosage based on their genetic information.
This investigation, conducted by scientists at the University of Pittsburgh, analyzed 16 genes that influence the body’s reaction to various medications.
DNA samples from 98,590 individuals involved in the National Institutes of Health’s All of Us Research Program were scrutinized and matched with available medical records.
Each participant had at least one genetic variation that could influence their response to specific medications, with the average individual carrying nine variations. Among those with both genetic and clinical information, 24.4% had been prescribed medications that, according to their genetic profiles, guidelines suggested should either have been substituted with a different drug or adjusted in dosage.
Nonetheless, the research did not ascertain whether patients faced side effects or if their medications were ineffective due to their genetic characteristics.
Dr. Philip Empey, the study’s senior author and an associate professor at the University of Pittsburgh’s school of pharmacy, asserts that understanding a patient’s genetic profile could minimize the trial-and-error approach often associated with medication prescriptions.
“Anything we can do to enhance our ability to predict the optimal medication and dosage from the outset will help reduce that trial and error,” he stated.

A pharmacist organizes medications at a pharmacy in Vancouver in October 2022. Genetic variations can influence patient responses to certain drugs, possibly prompting doctors to modify dosages or choose alternative treatments. (Darryl Dyck/The Canadian Press)
Identifying the appropriate medication
Among the most frequently prescribed drugs to participants with genetic profiles indicating a need for treatment modifications were omeprazole and pantoprazole for acid reflux, as well as atorvastatin for cholesterol management.
Empey notes that certain genetic variations can heighten the risk of muscle complications in patients taking statins like atorvastatin, which are utilized to diminish the chances of heart attack or stroke.
This insight could assist healthcare providers in selecting alternative medications or adjusting treatment plans.
“It enables clinicians to make informed choices, such as, ‘Perhaps not that cholesterol medication. We might start with a lower dose. There might be a ceiling dose. Maybe we need to monitor for specific side effects more closely,'” Empey elaborated.
For some drugs, the implications can be even more critical.
For instance, specialists consulted by CBC News indicate that genetic testing can help pinpoint patients who may not respond effectively to clopidogrel (Plavix), a medication intended to prevent blood clots post-cardiac stenting, allowing doctors to opt for a different treatment.

Dr. James Kennedy leads the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health. He emphasizes that while genetic testing can guide medication choices, other factors such as diet, lifestyle, and existing medications must also be taken into account. (CBC)
A guide, not an assurance
Dr. James Kennedy, who oversees the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health (CAMH), remarked that the study’s findings were not unexpected, though he was particularly impressed by the genetic diversity and representation of individuals of African descent.
Kennedy’s team has conducted genetic testing for around 11,000 patients, many of whom had previously tried multiple antidepressants without achieving desired results.
Approximately 8 to 10% of individuals metabolize certain commonly prescribed antidepressants at an unusually slow pace, leading to drug accumulation that could result in side effects, he noted.
He emphasized that genetic testing is particularly beneficial for patients who have experienced difficulties with various medications.
However, he cautioned that DNA testing alone does not guarantee how a patient will react to a specific medication; other variables such as current medications, smoking habits, and diet must also be considered.
“We present a blueprint of your tendencies and have a conversation about all the additional factors to consider before arriving at a final decision,” he explained.
A 2023 European clinical trial referenced in the study found that conducting genetic testing prior to prescribing certain medications decreased adverse drug reactions. Nonetheless, integrating such testing into routine medical practice in Canada presents challenges.

A researcher at the University of Calgary holds a diagnostic kit used for identifying genetic variations in February 2024. Although such testing could aid in customizing medications to suit individual patients, its widespread application in Canada has been hindered by cost and practical issues. (Jeff McIntosh/The Canadian Press)
Challenges in Canada for universal testing
Dr. Jacob Udell, a cardiologist in Toronto, acknowledged the study’s impressive nature, particularly in terms of the genetic diversity among participants, but noted that few healthcare professionals in Canada or the U.S. routinely assess patients for genetic variations that could influence their medication metabolism.
“It’s not something that’s typically on the radar of front-line clinicians,” he stated.
Udell pointed out that for numerous conditions, a doctor can prescribe a medication, observe the patient’s reaction, and make necessary adjustments without significant risks. This method may be more feasible than consistently screening patients for genetic variations.
He also questioned if making widespread testing a priority is sensible while Canada’s healthcare system is grappling with the challenge of providing basic services.
“We’re merely trying to ensure everyone has access to a family doctor,” he remarked.
In addition to the costs associated with genetic tests, Udell noted that clinicians would require access to the results and the expertise to interpret them accurately.
Empey concurred that implementing routine genetic testing would necessitate substantial investments in training, infrastructure, and new systems to facilitate result sharing among healthcare providers.
“The scientific basis is solid for many medications. The challenge for implementation is more about economics, process, and education,” he stated.
For the time being, Empey advises patients to inquire with their doctors or pharmacists about the potential benefits of genetic testing and to share any results they may have.
Udell cautioned that private genetic testing might become more prevalent for those who can afford it, “but that won’t assist those who cannot pay for the testing.”
